SCHEMBL16748445

SCHEMBL16748445

Cc1ccc(Nc2nc(N)nc(-n3c(C)nc4ccc(F)cc43)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 6/20 0.50
CYBB P04839 1/20 0.46
NOX5 Q96PH1 1/20 0.46
NOX3 Q9HBY0 1/20 0.46
NOX4 Q9NPH5 1/20 0.46
NOX1 Q9Y5S8 1/20 0.46
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
JAK2 O60674 1/20 0.43
DHFR P00374 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 2/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
BLM P54132 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748613 0.91 BMI1 (0.48) BMI1RAB9ANPC1DHFRMEN1
SCHEMBL16748437 0.91 BMI1 (0.48) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16748450 0.89 BMI1 (0.52) BMI1RAB9ANPC1JAK2DHFR
SCHEMBL16748533 0.89 BMI1 (0.64) BMI1DHFRMEN1KMT2ABLM
SCHEMBL16748587 0.89 BMI1 (0.47) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16748617 0.89 BMI1 (0.52) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16740732 0.87 PIK3CD (0.47) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16748610 0.87 BMI1 (0.49) BMI1DHFR
SCHEMBL16740843 0.87 BMI1 (0.51) BMI1CYBBNOX5NOX3NOX4
SCHEMBL16748528 0.87 BMI1 (0.66) BMI1DHFRL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885CYBB 4251/4885NOX5 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.